GlassScriptPhysician profile
Kafi Bridget Thomas
NPI 1376064246
$3,910.69
in general payments reported to CMS, 2019-2025
33 companies · $617 in 2025
The $617 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.50 · 2023: $1,284 · 2024: $1,994 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,300 · Education: $595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,300.14 |
| Education | $595.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $630.57 | 2023-2025 | Darzalex, Tecvayli, Erleada |
| Astrazeneca Pharmaceuticals LP | $365.95 | 2023-2025 | Tagrisso, Calquence, Enhertu |
| Daiichi Sankyo INC. | $215.54 | 2024 | Enhertu |
| Genzyme Corporation | $213.56 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $206.32 | 2023-2025 | Libtayo |
| Incyte Corporation | $205.25 | 2023-2025 | Jakafi |
| Taiho Oncology, INC. | $178.89 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $173.71 | 2023-2025 | Ninlaro, Hyqvia |
| E.R. Squibb & Sons, L.L.C. | $162.50 | 2022-2023 | Opdivo |
| Alexion Pharmaceuticals, INC. | $155.56 | 2023-2025 | Ultomiris |
| Gilead Sciences, INC. | $148.66 | 2023-2024 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $144.99 | 2023-2024 | |
| Pfizer INC. | $120.58 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $115.41 | 2023-2024 | Orgovyx |
| Lilly USA, LLC | $101.61 | 2023-2024 | Retevmo, Jaypirca, Verzenio |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $95.50 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $87.98 | 2023-2024 | Keytruda, Lynparza |
| Sanofi-Aventis U.S. LLC | $84.99 | 2023 | |
| Kyowa Kirin, INC. | $74.50 | 2023-2024 | Poteligeo |
| Janssen Pharmaceuticals, INC | $65.04 | 2023-2024 | Xarelto |
| Genentech USA, INC. | $50.06 | 2023-2024 | Phesgo, Itovebi |
| Novartis Pharmaceuticals Corporation | $40.51 | 2024-2025 | |
| Eisai INC. | $40.21 | 2024 | |
| Array Biopharma INC | $34.90 | 2023-2024 | Braftovi, Lorbrena, Xalkori |
| Karyopharm Therapeutics INC. | $33.65 | 2023 | Xpovio |
| Blueprint Medicines Corporation | $26.60 | 2024 | Ayvakit |
| Servier Pharmaceuticals LLC | $24.25 | 2025 | |
| Sobi, INC | $22.91 | 2025 | |
| Recordati_rare_diseases_inc. | $22.08 | 2023 | Sylvant |
| Seagen INC. | $21.17 | 2023 | Adcetris |
| Deciphera Pharmaceuticals INC. | $19.82 | 2025 | Romvimza, Qinlock |
| Legend Biotech USA INC. | $13.96 | 2025 | Carvykti |
| Abbvie INC. | $13.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kafi Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.